Prescription ·Strong evidence ·Reviewed May 2026
Ezetimibe is a lipid-lowering medication that reduces the intestinal absorption of dietary and biliary cholesterol. It is used either alone or, more commonly, in combination with a statin to lower LDL cholesterol. By blocking cholesterol uptake at the brush border of the small intestine, it provides an additive LDL reduction that complements the hepatic effects of statins.
The bottom line
Evidence rating strong. Most-documented uses: lowering elevated ldl cholesterol (primary hypercholesterolemia), adjunctive therapy with statins for additional ldl reduction, reducing cardiovascular events when added to statin therapy after acute coronary syndrome. 3 sources indexed (2002–2015), with 5 interaction records on file.
Core mechanism
Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) sterol transport protein located on the brush border membrane of enterocytes in the small intestine. NPC1L1 mediates the absorption of cholesterol and related phytosterols from the gut lumen into the enterocyte. By blocking this transporter, ezetimibe decreases the delivery of intestinal cholesterol to the liver, which lowers hepatic cholesterol stores and increases clearance of cholesterol from the blood by upregulating hepatic LDL receptors. Unlike bile acid sequestrants, it does not affect the absorption of triglycerides or bile acids; however, because cholesterol micelle formation overlaps with the absorption pathway of fat-soluble vitamins, reduced uptake of vitamins A, D, and E and of carotenoids can occur. Ezetimibe undergoes extensive enterohepatic recirculation as its active glucuronide metabolite, which prolongs its action at the absorption site.3,1
Can be taken with or without food at any time of day; food does not meaningfully affect efficacy. May modestly reduce absorption of fat-soluble vitamins (A, D, E) and carotenoids by interfering with intestinal cholesterol uptake. If used with a bile acid sequestrant, administer ezetimibe at least 2 hours before or 4 hours after the sequestrant.2
Nutrients this medication can lower over time, and what to replace.
Ezetimibe inhibits the intestinal sterol transporter NPC1L1 at the brush border of enterocytes, reducing absorption of dietary and biliary cholesterol. Because fat-soluble micronutrients are absorbed via overlapping micellar and lipid-uptake pathways, ezetimibe can modestly reduce absorption of lipid-soluble antioxidants such as alpha-tocopherol. Plasma tocopherol concentrations are also tightly coupled to circulating lipoproteins, so the LDL lowering itself can lower total (lipid-bound) vitamin E, though lipid-standardized tocopherol is generally preserved.
Carotenoids are absorbed in the intestine through lipid micelles and partly via NPC1L1-mediated and scavenger-receptor pathways shared with cholesterol uptake. By blocking NPC1L1 and lowering micellar cholesterol incorporation, ezetimibe can reduce intestinal uptake of carotenoids such as beta-carotene. Plasma carotenoid levels, which travel on lipoproteins, may fall further as LDL is reduced. Clinical trials with ezetimibe have reported lower circulating beta-carotene relative to baseline or comparator.
Psyllium can delay or reduce absorption of some oral drugs if taken at the same time as Ezetimibe.
Recommendation: Separate psyllium from Ezetimibe by at least 2 hours unless the prescriber gives different timing instructions.
Berberine may add modest lipid-lowering effects to Ezetimibe.
Recommendation: Use as part of the lipid plan, not as a substitute for prescribed therapy; recheck lipids after regimen changes.
Ezetimibe blocks intestinal absorption of cholesterol via the Niemann-Pick C1-Like 1 (NPC1L1) transporter. Because fat-soluble vitamin D shares a dependence on intact micellar lipid uptake in the small intestine, ezetimibe has the potential to modestly reduce vitamin D absorption. Clinical studies have generally found only small or non-significant effects on serum 25-hydroxyvitamin D, but individuals who are already vitamin D insufficient or who take low doses may see a measurable difference over time.
Recommendation: Routine vitamin D3 supplementation does not need to be stopped. For patients on long-term ezetimibe, especially those with baseline insufficiency, periodically check serum 25-hydroxyvitamin D and supplement to maintain adequate status. No strict dose-separation is required, though taking vitamin D3 with a fat-containing meal supports absorption.
As a fat-soluble vitamin absorbed through the same micellar lipid pathway affected by ezetimibe, vitamin E (tocopherol) absorption may be modestly reduced. Some pharmacology data show small decreases in serum alpha-tocopherol and carotenoids with cholesterol absorption inhibitors. The effect is generally minor and is partly offset because circulating tocopherol is carried on lipoproteins whose levels also fall with therapy.
Recommendation: No change to standard vitamin E intake is needed. Patients relying on vitamin E supplementation for a specific indication can take it with a fat-containing meal to optimize uptake. Routine monitoring is not required for typical dietary or supplemental doses.
Fish oil (EPA and DHA) primarily lowers triglycerides and modestly affects other lipid fractions through mechanisms distinct from ezetimibe's inhibition of cholesterol absorption. Combining the two addresses complementary parts of the lipid profile, and clinical use of omega-3s alongside cholesterol absorption inhibitors is common and generally well tolerated.
Recommendation: The combination is reasonable and complementary, particularly when both elevated LDL and elevated triglycerides are present. No dose separation is required. Monitor the full lipid panel to confirm benefit and continue standard cardiovascular risk management.
Numbered references. Citations throughout the page link here.
Simvastatin plus ezetimibe lowered LDL to a median of about 54 mg/dL versus 70 mg/dL with simvastatin alone and produced a modest but significant reduction in the composite of cardiovascular death, major coronary events, and stroke.
Ezetimibe 10 mg added to simvastatin produced significantly greater LDL cholesterol reductions than simvastatin alone across doses, with a safety profile comparable to placebo.
Identified NPC1L1 as the intestinal sterol transporter that is the molecular target of ezetimibe, establishing the mechanism of cholesterol absorption inhibition.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
